JB Chemicals & Pharmaceuticals reported a net profit of INR 208 crore for the quarter ended September 30, 2025, marking a 19 percent year-on-year increase from INR 175 crore in the same period last year. 

Total revenue from operations grew 8 percent to INR 1,085 crore, up from INR 1,001 crore in Q2 FY25. The company’s domestic formulations business expanded 9 percent to INR 644 crore, while international formulations revenue rose 7 percent to INR 441 crore. EBITDA for the quarter reached INR 319 crore, and the margin stood at approximately 29.4 percent.

Management noted that the company’s focus on consistent volume growth across key brands and a return to momentum in its CDMO business are driving performance.